Agenus Inc (AGEN) - Total Liabilities
Based on the latest financial reports, Agenus Inc (AGEN) has total liabilities worth $414.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Agenus Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Agenus Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Agenus Inc to evaluate short-term liquidity relative to the company's equity base.
Agenus Inc Competitors by Total Liabilities
The table below lists competitors of Agenus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GR Silver Mining Ltd
V:GRSL
|
Canada | CA$1.16 Million |
|
Tainergy Tech Co Ltd
TW:4934
|
Taiwan | NT$640.67 Million |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
USA | $16.29 Million |
|
Reef Casino Trust
AU:RCT
|
Australia | AU$91.42 Million |
|
Mincon Group plc
IR:MIO
|
Ireland | €59.18 Million |
|
Reyon Pharmaceutical Co Ltd
KO:102460
|
Korea | ₩239.99 Billion |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
Israel | ILA953.11 Million |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
USA | $66.83 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Agenus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGEN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agenus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agenus Inc (1999–2025)
The table below shows the annual total liabilities of Agenus Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $504.66 Million | -5.26% |
| 2024-12-31 | $532.70 Million | +15.23% |
| 2023-12-31 | $462.30 Million | -1.32% |
| 2022-12-31 | $468.46 Million | +12.06% |
| 2021-12-31 | $418.05 Million | -1.87% |
| 2020-12-31 | $426.01 Million | +10.17% |
| 2019-12-31 | $386.67 Million | +24.35% |
| 2018-12-31 | $310.95 Million | +45.15% |
| 2017-12-31 | $214.22 Million | +9.23% |
| 2016-12-31 | $196.11 Million | +14.35% |
| 2015-12-31 | $171.50 Million | +232.95% |
| 2014-12-31 | $51.51 Million | +31.01% |
| 2013-12-31 | $39.32 Million | -15.80% |
| 2012-12-31 | $46.69 Million | +14.90% |
| 2011-12-31 | $40.64 Million | -10.91% |
| 2010-12-31 | $45.61 Million | -27.42% |
| 2009-12-31 | $62.85 Million | -22.28% |
| 2008-12-31 | $80.86 Million | -11.72% |
| 2007-12-31 | $91.60 Million | +1.39% |
| 2006-12-31 | $90.35 Million | +25.04% |
| 2005-12-31 | $72.25 Million | +171.47% |
| 2004-12-31 | $26.61 Million | -23.60% |
| 2003-12-31 | $34.83 Million | +208.11% |
| 2002-12-31 | $11.31 Million | -35.84% |
| 2001-12-31 | $17.62 Million | +56.46% |
| 2000-12-31 | $11.26 Million | +161.91% |
| 1999-12-31 | $4.30 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more